Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET
Company Participants
Sonya Weigle - Chief People and Investor Relations Officer
Scott Braunstein - Chairman and Chief Executive Officer
Lisa Lejuwaan - Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy
Joseph Hulihan - Chief Medical Officer
Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Joseph Thome - TD Cowen
Andrew Tsai - Jefferies
Douglas Tsao - H.C. Wainwright
Marc Goodman - Leerink
Operator
Greetings and welcome to Marinus Pharmaceuticals' Second Quarter Financial Results and Business Update Call. [Operator Instructions]
It is my pleasure to introduce your host, Sonya Weigle, Chief People and Investor Relations Officer. You may now begin, Ms. Weigle.
Sonya Weigle
Thank you and good morning. With me from Marinus are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Lisa Lejuwaan, Senior Vice President and Business Unit Lead, Rare Genetic Epilepsy; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K.
I will now turn the call over to our CEO, Dr. Scott Braunstein.
Scott Braunstein
Thank you, Sonya, and thanks everyone for joining us this morning. On today's call, our team will highlight the significant commercial, clinical and operational progress that we have made throughout 2024. We'll also discuss our plans for the second half of the year and beyond, including how we're preparing for the upcoming Phase 3 readout in tuberous sclerosis complex and expanding access to ZTALMY for patients on a global scale.
Starting with ZTALMY. It has now been two years since our commercial launch in CDKL5 deficiency disorder, and I could not be prouder of the success that we have achieved in growing the brand in the US and the regulatory accomplishments globally. Launching a new product, particularly in the orphan epilepsy space, is no easy task. But our commercial team has proven its ability to be highly effective, attaining profitability on a commercial investment in the first quarter of 2024, well ahead of our initial expectations. We believe these efforts will only be bolstered by a considerable number of scientific presentations across several medical meetings by year-end.